Company Overview & History
Company Overview
| Company Name |
BrightPath Biotherapeutics Co., Ltd. |
| Location |
Corporate HeadquartersKojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo MAP
Kawasaki Research Laboratories
Cell Technology Laboratories Life Innovation Center 412, 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa MAP
|
| Established |
May 8, 2003 |
| Capital Stock |
6,700million yen（as of March 31, 2022） |
| Number of Employees |
38people（as of March 31, 2022） |
History
| May 2003 |
Established at Kurume, Fukuoka Prefecture |
| January 2006 |
Started a phase I clinical trial of ITK-1 for castration-resistant prostate cancer |
| November 2011 |
Reached an out-license agreement on ITK-1 with FUJIFILM Corporation |
| June 2013 |
Started a phase III clinical trial of ITK-1 for castration-resistant prostate cancer |
| June 2015 |
Interim analysis of the phase III study trial of ITK-1 in CRPC completed & the study continued as planned |
| October 2015 |
Started a phase I clinical trial of GRN-1201 for melanoma in the US
Listed on the Tokyo Stock Exchange (code:4594) |
| August 2016 |
Opened Kawasaki Research Laboratory at Kawasaki, Kanagawa prefecture |
| January 2017 |
Started a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US |
| July 2017 |
Changed company name from GreenPeptide to BrightPath Biotherapeutics |
| April 2018 |
Joined iPS-NKT development project promoted by RIKEN |
| May 2018 |
Opened the keys-code of the phase III double-blind placebo-controlled study for ITK-1 |
| May 2019 |
Terminated development of ITK-1 |
| June 2020 |
Started Phase I clinical trial of iPS-NKT for head and neck cancer |
| May 2022 |
Started Phase I clinical trial of HER2-targeted CAR-T cell therapy BP2301 |
| May 2022 |
Announced the early termination of a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US |
